减瘤性肾切除术后接受监测患者的生存预后因素
这项单中心回顾性研究分析了接受减瘤性肾切除术后进入监测的转移性肾细胞癌患者,采用IMDC评分和转移器官数目进行风险分层,发现有利风险患者的总生存、癌症特异性生存和无全身治疗生存均优于不利风险患者,提示有利风险患者可在一段时间内暂不启动全身治疗。
要点
- 中位无全身治疗生存期为23.6个月,中位总生存期为52.4个月。
- 有利风险患者的中位无全身治疗生存期为50.6个月,不利风险患者为11.1个月(P < .01)。
- 有利风险患者的中位总生存期为25.2个月,不利风险患者为7.3个月(P < .01)。
核心结论
- 基于IMDC评分和转移器官数目的风险分层,有利风险患者可在监测下暂不启动全身治疗一段时间,从而延迟全身治疗副作用暴露。
研究设计与样本
- 单中心回顾性研究,纳入接受减瘤性肾切除术后监测的初治转移性肾细胞癌患者。
主要发现
- 中位无全身治疗生存期为23.6个月(95% CI:15.1-40.6),中位无干预生存期为11.8个月(95% CI:8.0-18.4)。
- 中位癌症特异性生存期为54.2个月(95% CI:46.2-71.4),中位总生存期为52.4个月(95% CI:40.3-66.8)。
- 有利风险患者相比不利风险患者的中位无全身治疗生存期为50.6个月 vs 11.1个月(P < .01)。
- 有利风险患者相比不利风险患者的中位生存期为25.2个月 vs 7.3个月(P < .01)。
- 有利风险患者相比不利风险患者的中位癌症特异性生存期为71.4个月 vs 46.2个月(P = .02)。
关键数值与推荐
- IMDC评分≤1且转移器官部位≤2个定义为有利风险。
临床怎么用
- 作者认为,基于IMDC评分和转移器官数目的风险分层,有利风险患者可在监测下暂不启动全身治疗一段时间,从而延迟全身治疗副作用暴露。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The clinical course of patients being placed on surveillance in a cohort of systemic therapy-naïve patients who undergo cytoreductive nephrectomy is not well documented. Thus, we evaluated the clinical course of patients placed on surveillance following cytoreductive nephrectomy and identified predictors of survival. MATERIALS AND METHODS: In this large single-institution study, we retrospectively analyzed metastatic renal cell carcinoma patients who underwent cytoreductive nephrectomy followed by surveillance. Predictors of survival were evaluated using the Kaplan-Meier method with a log-rank test. Patients were risk stratified based on IMDC (International mRCC Database Consortium) and number of metastatic sites (Rini score), with IMDC score ≤1 and ≤2 metastatic organ sites considered favorable risk. Primary end point was systemic therapy-free survival. Secondary end points included intervention-free survival, cancer-specific survival, and overall survival. RESULTS: Median systemic therapy-free survival was 23.6 months (95% CI: 15.1-40.6), intervention-free survival was 11.8 months (95% CI: 8.0-18.4), cancer-specific survival was 54.2 months (95% CI: 46.2-71.4), and overall survival 52.4 months (95% CI: 40.3-66.8). Favorable-risk patients compared to unfavorable-risk patients had longer systemic therapy-free survival (50.6 vs 11.1 months, P < .01), survival (25.2 vs 7.3, P < .01), and cancer-specific survival (71.4 vs 46.2 months, P = .02). CONCLUSIONS: Using risk stratification based on IMDC and number of metastatic sites, surveillance in favorable-risk patients can be utilized for a period without the initiation of systemic therapy. This approach can delay patients' exposure to the side effects of systemic therapy.
引用
- Reese SW, Khaleel S, Silagy A, et al. Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive Nephrectomy. J Urol. 2023. PMID: 37167628. doi:10.1097/JU.0000000000003549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。